论文部分内容阅读
目的研究重组组织型纤维蛋白溶酶原激活剂(栓体舒)对急性ST段抬高心肌梗死患者溶栓的疗效和安全性。方法随机选择住院的急性ST段抬高心肌梗死发病6h以内患者,分别给予栓体舒或尿激酶,观察主要疗效和安全性指标。结果共入组60例患者,栓体舒溶栓患者30例,尿激酶溶栓患者30例,溶栓后栓体舒血管再通率(24/30,80%)与尿激酶(18/30,60%)差异有统计学意义(P<0.05),不良反应中栓体舒组发热发生率3.3%,低血压发生率6.7%,出血发生率3.3%均为消化道出血,经治疗而愈;尿激酶组发热伴皮疹6.7%,低血压3.3%,消化道出血6.7%,二组均未发生颅内出血,二组的不良反应均无显著性差异(P>0.05)。结论栓体舒溶栓治疗较尿激酶溶栓治疗血管再通率高、过敏反应及出血发生率低,程度轻,是一种安全有效的溶栓剂。
Objective To study the efficacy and safety of recombinant tissue plasminogen activator (PTS) in thrombolysis in patients with acute ST-segment elevation myocardial infarction. Methods Randomly selected inpatients with acute ST-segment elevation myocardial infarction within 6 hours after onset of the disease, respectively, given Shu Shu or urokinase, to observe the main efficacy and safety indicators. Results A total of 60 patients were enrolled in this study. Thromboembolism in 30 patients, thrombolysis in 30 patients, thrombolysis thrombolysis after thrombolysis (24/30, 80%) and urokinase , 60%) (P <0.05). Adverse reactions occurred in 3.3% of patients in Shu Shu group, 6.7% of hypotension and 3.3% of bleeding were all gastrointestinal bleeding. After treatment, the more hemorrhage occurred Urokinase fever with rash 6.7%, hypotension 3.3%, gastrointestinal bleeding 6.7%, no intracranial hemorrhage occurred in both groups, no significant difference between the two groups (P> 0.05). Conclusions Thrombolytic suppository is a safe and effective thrombolytic agent, which is more effective than urokinase thrombolysis in treating recanalization rate, allergic reaction and hemorrhage.